Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (Nasdaq: ELVN) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics, with a focus on precision medicines for unmet medical needs. Its lead candidate, ELVN-001, is an ATP-competitive tyrosine kinase inhibitor designed to target the BCR-ABL fusion that drives… From the company’s description.
In fiscal 2025, Enliven Therapeutics, Inc. reported a net loss of $103.69M. Operations used $70.30M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Enliven Therapeutics, Inc. does
In the company’s own words
Enliven Therapeutics, Inc. (Nasdaq: ELVN) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics, with a focus on precision medicines for unmet medical needs. Its lead candidate, ELVN-001, is an ATP-competitive tyrosine kinase inhibitor designed to target the BCR-ABL fusion that drives chronic myeloid leukemia (CML); it is being evaluated in a Phase 1 clinical trial. The company plans a Phase 3 trial for ELVN-001 and conducts research on additional small-molecule programs, including opportunities in Graves’ disease. Its other clinical-stage candidate, ELVN-002, is a central nervous system-penetrant HER2 inhibitor; the company is exploring strategic alternatives for the program while prioritizing ELVN-001. Enliven has worldwide development and commercial rights to its pipeline assets and relies on third parties to manufacture its candidates. The company was co-founded in 2019 and merged with Imara in 2023.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BURLINGAME, CA
- Fiscal year end
- December
- CIK
- 1672619
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Enliven Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Enliven Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Enliven Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Enliven Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Enliven Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”